Literature DB >> 11683253

Pharmaceutical significance of the cyclic imide form of recombinant human glial cell line derived neurotrophic factor.

D Markell1, J Hui, L Narhi, D Lau, C LeBel, D Aparisio, J Lile, S Jing, D Yui, B S Chang.   

Abstract

PURPOSE: The purpose of this paper is to determine the significance of cyclic imide formation of an aspartic acid residue during storage on the pharmaceutical quality of a recombinant human glial cell line-derived neurotrophic factor (rhGDNF) formulation.
METHODS: A combination of chromatography, peptide mapping, mass spectroscopy, and protein sequencing was used to purify and characterize the degradation product. Circular dichroism, 1,8-ANS and heparin binding, melting temperature determination, bioassays, and preclinical pharmacokinetic and toxicology testing were performed to examine its equivalence to native rhGDNF.
RESULTS: The rhGDNF with cyclic imide at aspartic acid residue 96 showed identical activity, structure, pharmacokinetic profile, and toxicity profile to the native rhGDNF.
CONCLUSIONS: Formation of cyclic imide at aspartic acid residue 96 does not affect the pharmaceutical quality of the rhGDNF formulation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11683253     DOI: 10.1023/a:1013058532425

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  13 in total

1.  Expression of the proto-oncogene Ret, a component of the GDNF receptor complex, persists in human substantia nigra neurons in Parkinson's disease.

Authors:  D G Walker; T G Beach; R Xu; J Lile; K D Beck; E G McGeer; P L McGeer
Journal:  Brain Res       Date:  1998-05-11       Impact factor: 3.252

Review 2.  The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation.

Authors:  J L Cleland; M F Powell; S J Shire
Journal:  Crit Rev Ther Drug Carrier Syst       Date:  1993       Impact factor: 4.889

3.  GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF.

Authors:  S Jing; D Wen; Y Yu; P L Holst; Y Luo; M Fang; R Tamir; L Antonio; Z Hu; R Cupples; J C Louis; S Hu; B W Altrock; G M Fox
Journal:  Cell       Date:  1996-06-28       Impact factor: 41.582

4.  Glial cell line-derived neurotrophic factor: selective reduction of the intermolecular disulfide linkage and characterization of its disulfide structure.

Authors:  M Haniu; J Hui; Y Young; J Le; V Katta; R Lee; G Shimamoto; M F Rohde
Journal:  Biochemistry       Date:  1996-12-24       Impact factor: 3.162

5.  Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease.

Authors:  J H Kordower; S Palfi; E Y Chen; S Y Ma; T Sendera; E J Cochran; E J Cochran; E J Mufson; R Penn; C G Goetz; C D Comella
Journal:  Ann Neurol       Date:  1999-09       Impact factor: 10.422

6.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons.

Authors:  L F Lin; D H Doherty; J D Lile; S Bektesh; F Collins
Journal:  Science       Date:  1993-05-21       Impact factor: 47.728

Review 7.  Development of mesencephalic dopaminergic neurons and the transforming growth factor-beta superfamily.

Authors:  K Krieglstein; C Suter-Crazzolara; K Unsicker
Journal:  J Neural Transm Suppl       Date:  1995

8.  Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides.

Authors:  R Tyler-Cross; V Schirch
Journal:  J Biol Chem       Date:  1991-11-25       Impact factor: 5.157

Review 9.  Glial cell line-derived neurotrophic factor (GDNF): a drug candidate for the treatment of Parkinson's disease.

Authors:  R Grondin; D M Gash
Journal:  J Neurol       Date:  1998-11       Impact factor: 4.849

10.  Chemical pathways of peptide degradation. IV. Pathways, kinetics, and mechanism of degradation of an aspartyl residue in a model hexapeptide.

Authors:  C Oliyai; R T Borchardt
Journal:  Pharm Res       Date:  1993-01       Impact factor: 4.200

View more
  2 in total

Review 1.  Stability of protein pharmaceuticals: an update.

Authors:  Mark Cornell Manning; Danny K Chou; Brian M Murphy; Robert W Payne; Derrick S Katayama
Journal:  Pharm Res       Date:  2010-02-09       Impact factor: 4.200

2.  Detection and quantitation of succinimide in intact protein via hydrazine trapping and chemical derivatization.

Authors:  Joshua J Klaene; Wenqin Ni; Joshua F Alfaro; Zhaohui Sunny Zhou
Journal:  J Pharm Sci       Date:  2014-07-14       Impact factor: 3.534

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.